WallStreetZenWallStreetZen

NASDAQ: ATRA
Atara Biotherapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for ATRA

Based on 1 analyst offering 12 month price targets for Atara Biotherapeutics Inc.
Min Forecast
$2.30+275.82%
Avg Forecast
$2.30+275.82%
Max Forecast
$2.30+275.82%

Should I buy or sell ATRA stock?

Based on 1 analyst offering ratings for Atara Biotherapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ATRA stock forecasts and price targets.

ATRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is ATRA forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is ATRA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ATRA revenue forecast

What is ATRA's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$106.6M+207.27%
Avg 2 year Forecast
$29.2M-15.83%
ATRA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ATRA revenue growth forecast

How is ATRA forecast to perform vs Biotechnology companies and vs the US market?
Company
142.24%
Industry
35.65%
Market
10.58%
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATRA$0.61$2.30+275.82%Hold
ALRN$3.41$19.00+457.18%Strong Buy
PASG$1.19$13.00+992.44%Strong Buy
VTVT$24.66N/AN/A
ANVS$6.65$19.33+190.72%Buy

Atara Biotherapeutics Stock Forecast FAQ

Is Atara Biotherapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ATRA) stock is to Hold ATRA stock.

Out of 1 analyst, 0 (0%) are recommending ATRA as a Strong Buy, 0 (0%) are recommending ATRA as a Buy, 1 (100%) are recommending ATRA as a Hold, 0 (0%) are recommending ATRA as a Sell, and 0 (0%) are recommending ATRA as a Strong Sell.

If you're new to stock investing, here's how to buy Atara Biotherapeutics stock.

What is ATRA's revenue growth forecast for 2024-2025?

(NASDAQ: ATRA) Atara Biotherapeutics's forecast annual revenue growth rate of 142.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.58%.

Atara Biotherapeutics's revenue in 2024 is $34,704,000.On average, 2 Wall Street analysts forecast ATRA's revenue for 2024 to be $12,840,574,876, with the lowest ATRA revenue forecast at $11,592,461,605, and the highest ATRA revenue forecast at $14,088,688,146.

In 2025, ATRA is forecast to generate $3,517,355,391 in revenue, with the lowest revenue forecast at $1,926,658,208 and the highest revenue forecast at $5,108,052,574.

What is ATRA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ATRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ATRA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ATRA price target, the average ATRA price target is $2.30, with the highest ATRA stock price forecast at $2.30 and the lowest ATRA stock price forecast at $2.30.

The Wall Street analyst predicted that Atara Biotherapeutics's share price could reach $2.30 by Apr 1, 2025. The average Atara Biotherapeutics stock price prediction forecasts a potential upside of 275.82% from the current ATRA share price of $0.61.

What is ATRA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ATRA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.